📚 Nephrology — L4: Chronic Kidney Disease (Ckd)

📚 Lecture Overview

This lecture covers Chronic Kidney Disease (CKD), defining its staging, pathophysiology, and multi-system clinical consequences. It details the diagnostic approach using GFR formulas and albuminuria levels, and outlines comprehensive medical and renal replacement therapies to slow disease progression and manage complications.

🎯 Key Concepts & Definitions

• Chronic Kidney Disease (CKD): The presence of kidney damage or an estimated glomerular filtration rate (eGFR) less than 60 ml/min per 1.73 square meters, persisting for 3 months or more.
• Uremia: The clinical syndrome and systemic tissue damage resulting from the retention of urea and other nitrogenous waste products.
• Isothenuria: The production of excessive urine with a low, fixed specific gravity, typically seen in early CKD stages.
• Uremic Frost: A rare manifestation where urea is deposited in sweat glands, crystallizes on the skin during sweat evaporation, and appears as a white powder.
• Nephron Hyperfiltration: The adaptive response of surviving nephrons to maintain GFR after renal injury, which ultimately causes glomerular capillary damage and glomerulosclerosis.

Main Content

1. Classification and Etiology of CKD

• Classified into 6 GFR categories (G1 to G5, with G3 split into G3a and G3b) and 3 albuminuria levels (A1, A2, A3 based on ACR).
• G1: GFR $≥$ 90 ml/min/1.73 m²
• G2: GFR 60 to 89 ml/min/1.73 m²
• G3a: GFR 45 to 59 ml/min/1.73 m²
• G3b: GFR 30 to 44 ml/min/1.73 m²
• G4: GFR 15 to 29 ml/min/1.73 m²
• G5: GFR < 15 ml/min/1.73 m² or dialysis
• Albuminuria Levels: A1 (<30 mg/gm), A2 (30-299 mg/gm), A3 (>300 mg/gm).
• Global causes: Diabetes mellitus type 2 is the most common cause worldwide.
• Local causes: Hypertension is the most common cause in Egypt. Other causes include primary/secondary glomerulonephritis, chronic tubulointerstitial nephritis (NSAIDs), hereditary diseases, and obstructive uropathy.

2. Pathophysiology and Progression

• Initial injury triggers remaining nephrons to undergo hyperfiltration and compensatory hypertrophy.
• Stimulated mesangial cells release TGF-β, driving secondary focal segmental glomerulosclerosis (FSGS) and eventually global sclerosis.
• Non-Modifiable Risk Factors: Older age, male gender, African American ethnicity, history of AKI, childhood renal disease, family history of CKD, and cardiovascular disease.
• Modifiable Risk Factors: Systemic hypertension, marked proteinuria (A3), metabolic factors (insulin resistance, dyslipidemia, hyperuricemia), obesity, smoking, and gout.

3. Clinical Manifestations (Systemic Effects)

• Electrolytes: Hyperkalemia (impaired excretion at GFR <10), hyperphosphatemia, and hypocalcemia (diminished 1-alpha-hydroxylase activity and lack of active Vitamin D).
• Water Balance: Volume overload leading to lower limb edema, pulmonary congestion, and secondary hypertension.
• Endocrine and Bone:
• Decreased erythropoietin (EPO) leading to normocytic normochromic anemia.
• Secondary Hyperparathyroidism driven by hypocalcemia, causing bone resorption (Osteitis Fibrosa Cystica).
• Acid-Base: Failure to excrete $H^+$ and diminished $HCO_3^-$ absorption resulting in metabolic acidosis.
• Neurological/Hematological: Uremic encephalopathy (asterixis), platelet dysfunction causing coagulopathy, and uremic pericarditis.

4. Diagnosis and Investigations

• eGFR Calculation: Estimated using Cockcroft-Gault, MDRD, or CKD-EPI (creatinine or cystatin-c) formulas.
• Urine ACR: Assesses albuminuria severity (Mild <30, Moderate 30-299, Severe >300 mg/g).
• Renal Ultrasound: Typically reveals small atrophic kidneys with loss of corticomedullary differentiation and decreased vascularity on Doppler.
• Complication Screening: Elevated serum creatinine/urea, hyperkalemia, hyperphosphatemia, metabolic acidosis on ABG, and low Hb levels.

5. Medical Treatment and Management

• Slowing Progression: Target blood pressure <130/80 using ACEi or ARBs (when GFR >30) and loop diuretics. Target HbA1c <7% using SGLT2 inhibitors and insulin.
• Hyperkalemia Management: Shift $K^+$ intracellularly (glucose + insulin, bicarbonate, salbutamol), increase urinary excretion (loop diuretics), or remove via stool using exchange resins (polystyrene sulfonate, zirconium cyclosilicate).
• Mineral & Bone Disorder: Phosphate restriction (<1000 mg/day) with phosphate binders (sevelamer, calcium acetate), active Vitamin D (alphacalcidol), and calcimimetics (cinacalcet) for high PTH.
• Anemia Treatment: Synthetic EPO (alpha, beta, darbepoetin) and iron supplementation targeting Hb 10-11.5 g/dl.
• Nutritional Therapy: Protein restriction to 0.75 g/kg/day in stages 1-3 and 0.6 g/kg/day in stages 4-5.
• Dialysis Indications: Absolute clinical indicators include uremic encephalopathy (coma/convulsions), pericarditis, and refractory volume overload. Absolute biochemical indicators include severe metabolic acidosis (pH <7.2) and persistent hyperkalemia (>5.5) refractory to medical management.

📊 Visual Learning

💡 Important Points to Remember

• Definition Rule: CKD requires structural kidney damage or eGFR <60 ml/min/1.73 m² persisting for $≥$ 3 months.
• Leading Causes: Diabetes mellitus type 2 is #1 worldwide; Hypertension is #1 in Egypt.
• Bone Disease Mnemonic/Concept: Low active Vitamin D $\rightarrow$ Hypocalcemia $\rightarrow$ High PTH $\rightarrow$ Osteitis Fibrosa Cystica (High turnover bone disease).
• Anemia Type: Primarily normocytic, normochromic anemia due to erythropoietin deficiency (90% made by kidneys, 10% by liver).
• Urine Specific Gravity: Unlike acute renal failure, chronic renal failure features low and fixed specific gravity (isothenuria).
• Kidney Size: Ultrasound shows small, atrophic kidneys with loss of corticomedullary differentiation (except in diabetic nephropathy where kidneys can remain large).
• Blood Pressure Target: Strict control aiming for < 130/80 mmHg.
• Protein Restriction: Restrict dietary protein to 0.6 g/kg/day in stages 4-5 to reduce nitrogenous waste and progression.
• Hyperkalemia Emergency Treatment: Always shift potassium intracellularly first with glucose and insulin or bicarbonate/salbutamol before utilizing elimination therapies.
• Common Confusion: Do not confuse ARF (normal/large kidneys, preserved corticomedullary differentiation) with CRF (small, shrunken kidneys).

⚠️ Common Exam Questions

• MCQ Trick: Examiners often ask about kidney size in renal failure. They will present a case of chronic renal failure but list "normal or large kidneys" as an option (which occurs in diabetic nephropathy or amyloidosis, but classic CKD features small, atrophic kidneys).
• The RAAS Trap: Students often forget that failing kidneys sense hypoperfusion and paradoxically activate the Renin-Angiotensin-Aldosterone System, driving secondary hypertension, not hypotension.
• Dialysis Thresholds: Questions frequently test absolute versus relative indications for dialysis. Remember that uremic pericarditis and encephalopathy (coma/convulsions) are absolute clinical indications requiring immediate dialysis regardless of exact lab values.
• Bone Turnover Distinctions: Be prepared to differentiate high-turnover bone disease (osteitis fibrosa cystica due to secondary hyperparathyroidism) from low-turnover forms (adynamic bone disease or osteomalacia).

📝 Quick Review Checklist

I can define CKD and state the duration criterion (3 months)
I understand the 6 GFR stages (G1-G5) and 3 albuminuria classes (A1-A3)
I can explain the pathophysiology of hyperfiltration and TGF-$\beta$ release
I know why hypocalcemia and secondary hyperparathyroidism develop in CKD
I can differentiate acute renal failure from chronic renal failure on ultrasound and labs
I can list the absolute indications for initiating renal replacement therapy (dialysis)
I know the medical management strategies for hyperkalemia, hyperphosphatemia, and metabolic acidosis
I can calculate or recognize eGFR formulas (Cockcroft-Gault, MDRD, CKD-EPI)